BioAtla, Inc. (BCAB)
NASDAQ (NMS) NASDAQ (NMS) Primary 
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
BioAtla, Inc. ( BCAB ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay Short - Co-Founder, CEO & Chairman Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Richard Waldron - Senior VP & CFO Conference Call Participants Julie Miller Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2025 Earnings Call.
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Eric L. Sievers - Chief Medical Officer Jay M.
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee – BTIG Reni Benjamin - Citizens JMP Arthur He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla First Quarter 2025 Earnings Call.
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Arthur He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Fourth Quarter and Fiscal Year 2024 Earnings Call.
BioAtla Cuts 30% of Jobs in Restructuring Effort
The San Diego biopharmaceutical company, which focuses on treating solid tumor cancers, said Thursday its workforce reduction is part of an effort to extend its runway beyond key clinical readouts in the first half of 2026.
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know
BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call.
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Ozuriftamab Vedotin shows promising Phase 2 results and received FDA Fast Track Designation, enhancing its potential.
BioAtla: Numerous Catalysts Coming In Q4
BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with Context Therapeutics providing some runway extension. The company's cash position poses a significant risk, necessitating future fundraising, and potentially leading to substantial dilution and market volatility.
Michael Burry buys 634,000 shares of this $1 penny stock
When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Arthur He - H.C. Wainwright Operator Good day, everyone.
3 Penny Stocks With 735% Average Upside, According to Wall Street
With the third quarter in full swing, the bulls have not lost their grip on equities.
